These agents, which include tumor necrosis factor (TNF) inhibitors, interleukin (IL)-12/IL-23 inhibitors, and IL-17 inhibitors, work by targeting specific pathways involved in the pathogenesis of PRP. This evidence concerns the gene IL23A and familial pityriasis rubra pilaris.